Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects

• Main Authors: Min Young Park (Author), Sungyeun Bae (Author), Jung A Heo (Author), Mihee Park (Author), YuKyung Kim (Author), Jumi Han (Author), In‐Jin Jang (Author), Kyung‐Sang Yu (Author), Jaeseong Oh (Author)
• Format: Book
• Published: Wiley, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Bersiporocin, a novel first‐in‐class prolyl‐tRNA synthetase (PRS) inhibitor currently under clinical development, was shown to exert an antifibrotic effect through the downregulation of collagen synthesis in various pulmonary fibrosis models. The aim of this first‐in‐human, randomized, doub...